Document:

Exhibit 10.3

 

Purple Innovation, Inc.

2017 EQUITY INCENTIVE PLAN

 

Amended and Restated Option Grant Agreement

 

This Amended and Restated Option Grant Agreement
modifies the Option Grant Agreement dated October 1, 2018 and evidences the grant of a Nonqualified Stock Option (the “Initial
Grant”) and an agreement to grant Nonqualified Stock Options in the future (the “Future Grants”), pursuant to
the provisions of the Purple Innovation, Inc. 2017 Equity Incentive Plan (the “Plan”) to the individual whose name
appears below (the “Participant”), covering the specific number of shares of stock set forth below, pursuant to the
provisions of the Plan and on the following express terms and conditions (capitalized terms not otherwise defined herein shall
have the meaning ascribed thereto in the Plan):

 

	1. 	 	Name of Participant: Mark Watkins

     

	2. 	 	Initial Grant. The Initial Grant is comprised of an option to purchase 322,812 Common Shares of Purple Innovation,
    Inc. (the “Company”). The grant date of the Initial Grant is October 1, 2018 (the “Initial Grant Date”).

	3. 	 	Future Grants. Provided that the Participant continues to
                    be employed by the Company or any of its subsidiaries, the Company shall automatically grant to Participant
                    an option to purchase 71,736 Common Shares on each of the following dates, or, if such date is a weekend or
                    holiday, the next following business day (each a “Future Grant Date”):

                     

	 	 	 •	November 6, 2018
	 	 	 •	November 6, 2019
	 	 	 •	November 6, 2020

	4. 	 	 Exercise Price per Share:

         

	 	 	(a) 	Initial Grant. The exercise price of the Initial Grant shall be the
        greater of (i) the closing price of the Company’s Common Shares on the Initial Grant Date or (ii) the trailing sixty
        (60) day volume weighted average price of the Company’s Common Shares determined as of the Initial Grant Date.

         

	 	 	(b) 	Future Grants. The exercise price of each Future Grant shall be equal to the trailing thirty (30) day volume weighted
    average price of the Company’s Common Shares determined as of the respective Future Grant Date.

 

	5.	 	Vesting and Exercisability:
	 	 	 
	 	 	(a) 	Initial Grant. The Initial Grant shall be subject to four-year monthly
        vesting following an initial 25% “cliff”; the date of the 25% “cliff” is November 6, 2018. Vesting
        of the remaining 75% will occur on the first day of each calendar month thereafter. “Cliff” means herein that
        no vesting will occur until the date when the first 25% vests and the remaining 75% begins to vest monthly.

         

	 	 	(b)	Future Grants. Each Future Grant shall be subject to four-year monthly
        vesting following an initial one year 25% “cliff”; the date of the 25% one year “cliff” is the
        first anniversary date of the respective grant. Vesting of the remaining 75% will occur on the first day of each calendar
        month thereafter. “Cliff” means herein that no vesting will occur until the date when the first 25% vests
        and the remaining 75% begins to vest monthly.

         

	 	 	(c)	Termination. If Participant’s employment with the Company is terminated for Cause (as defined in the Participant’s
    Offer Letter of even date herewith), all of the Participant’s options issued under the Initial Grant or any Future Grant,
    whether vested or unvested, then outstanding shall be immediately forfeited and cancelled without payment.

 

	6. 	 	Change in Control: Notwithstanding the foregoing, upon a Change in Control (as defined in the Participant’s
    Offer Letter of even date herewith), the options issued under the Initial Grant or any Future Grant that are then outstanding
    shall vest as provided in the Plan.

 

	7. 	 	Clawback: The Initial Grant and each Future Grant is subject to any Company clawback policy as may be adopted or
    amended from time to time.

 

	8. 	 	Exercise:
	 	 	 
	 	 	With respect to the Initial Grant and any Future Grant, the
Exercise Price shall be payable, at the Participant’s election (A) in cash; (B) if there is a public market for the Common
Shares at the time of exercise, by means of a broker-assisted “cashless exercise” pursuant to which the Company is
delivered a copy of irrevocable instructions to a stockbroker to sell the Common Shares otherwise deliverable upon the exercise
of the option and to deliver promptly to the Company an amount equal to the Exercise Price or (C) by a “net exercise”
method whereby the Company withholds from the delivery of the Common Shares for which such option was exercised that number of
Common Shares having a Fair Market Value equal to the aggregate Exercise Price for the Common Shares for which such option was
exercised. Any fractional Common Shares shall be settled in cash.

 

	9. 	 	Expiration/Termination of Option: Each option shall have a term of five years. For the avoidance of doubt, to the
    extent not expired, terminated or cancelled earlier in accordance with the terms of Plan, the Initial Grant shall expire on
    October 1, 2023. The provisions of Section 7 of the Plan regarding death, Disability, Retirement and termination of employment
    (with and without Cause) shall apply.

    

    

     

    

 

Purple Innovation, Inc.

 

	By:	 /s/ Terry V. Pearce	 	 November 9, 2018	 
	 	
        Terry V. Pearce

        Chairman of the Board
	 	Dated	 

 

	Agreed to and Accepted by:	 
	 	 	 	 
	 /s/ Mark A. Watkins	 	 November 9, 2018	 
	Mark A. Watkins	 	DatedExhibit 4.1

 

AMENDMENT

TO

ACTINIUM PHARMACEUTICALS, INC. WARRANT TO PURCHASE COMMON STOCK

 

Pursuant to Section 9(a) of the Warrant to Purchase Common Stock
of (the “Warrant”) of Actinium Pharmaceuticals, Inc. (the “Company”), originally dated December
17, 2012, issued to Amrosan LLC in the amount of 375,556 warrant shares, the Board of Directors of the Company has duly adopted
a resolution approving this Amendment to the Warrant to extend the term of the Warrant to February 21, 2022 as follows:

 

		1.	Section 1 of the Warrant is hereby amended to read
in its entirety as follows:

 

“Term
of Warrant. Subject to the terms and conditions set forth herein, this Warrant shall be exercisable, in whole or in part,
during the term commencing (“Issuance Date”) December 17, 2012 (the “Warrant Issue Date”),
and ending at 5:00 p.m., Eastern Time on February 21, 2022 and shall be void thereafter.”

 

		2.	All other terms and provisions of the Warrant shall
remain unchanged and in full force and effect as written.

 

IN WITNESS WHEREOF, this
Amendment to the Warrant is made effective this 8th day of November, 2018.

 

	 	 	ACTINIUM PHARMACEUTICALS, INC.
	 	 	 	 
	 	 	By:	/s/ David Nicholson
	 	 	Name:	David Nicholson
	 	 	Title:	Chairman Compensation CommitteeExhibit 4.2

 

AMENDMENT

TO

ACTINIUM PHARMACEUTICALS, INC. WARRANT TO PURCHASE COMMON STOCK

 

Pursuant to Section 9(a) of the Warrant to Purchase Common Stock
of (the “Warrant”) of Actinium Pharmaceuticals, Inc. (the “Company”), originally dated December
17, 2012, issued to Carnegie Hill Partners in the amount of 353,023 warrant shares, the Board of Directors of the Company has duly
adopted a resolution approving this Amendment to the Warrant to extend the term of the Warrant to February 21, 2022 as follows:

 

	 	1.	Section 1 of the Warrant is hereby amended to read in its entirety as follows:

 

“Term
of Warrant. Subject to the terms and conditions set forth herein, this Warrant shall be exercisable, in whole or in part,
during the term commencing (“Issuance Date”) December 17, 2012 (the “Warrant Issue Date”),
and ending at 5:00 p.m., Eastern Time on February 21, 2022 and shall be void thereafter.”

 

	 	2.	All other terms and provisions of the Warrant shall remain unchanged and in full force and effect as written.

 

IN WITNESS WHEREOF, this
Amendment to the Warrant is made effective this 8th day of November, 2018.

 

	 	 	ACTINIUM PHARMACEUTICALS, INC.
	 	 	 	 	 
	 	 	By:	 	 /s/ David Nicholson
	 	 	Name:	 	David Nicholson
	 	 	Title:	 	Chairman Compensation CommitteeExhibit 4.3

 

AMENDMENT

TO

ACTINIUM PHARMACEUTICALS, INC. WARRANT TO PURCHASE COMMON STOCK

 

Pursuant to Section 9(a) of the Warrant to Purchase Common Stock
of (the “Warrant”) of Actinium Pharmaceuticals, Inc. (the “Company”), originally dated December
17, 2012, issued to Bioche Asset Management, LCC in the amount of 721,068 warrant shares, the Board of Directors of the Company
has duly adopted a resolution approving this Amendment to the Warrant to extend the term of the Warrant to February 21, 2022 as
follows:

 

	 	1.	Section 1 of the Warrant is hereby amended to read in its entirety as follows:

 

“Term
of Warrant. Subject to the terms and conditions set forth herein, this Warrant shall be exercisable, in whole or in part,
during the term commencing (“Issuance Date”) December 17, 2012 (the “Warrant Issue Date”),
and ending at 5:00 p.m., Eastern Time on February 21, 2022 and shall be void thereafter.”

 

	 	2.	All other terms and provisions of the Warrant shall remain unchanged and in full force and effect as written.

 

IN WITNESS WHEREOF, this
Amendment to the Warrant is made effective this 8th day of November, 2018.

 

	 	ACTINIUM PHARMACEUTICALS, INC.
	 	 	 
	 	By:	/s/ David Nicholson
	 	Name:	David Nicholson
	 	Title:	Chairman Compensation Committeecsgs-ex1022aj_103.htm

Pages where confidential treatment has been requested are stamped “Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission,” and places where information has been redacted have been marked with (***). 

Exhibit10.22AJ

 

 

THIRTY-FOURTH AMENDMENT

TO THE

CSG MASTER SUBSCRIBER MANAGEMENT SYSTEM AGREEMENT

BETWEEN

csg SYSTEMS, INC.

AND

COMCAST CABLE COMMUNICATIONS MANAGEMENT, LLC

 

 

This Thirty-fourth AMENDMENT (the “Amendment”) is made by and between CSG Systems, Inc. (“CSG”) and Comcast Cable Communications Management, LLC (“Customer”).  CSG and Customer entered into a certain CSG Master Subscriber Management System Agreement (CSG document no. 2501940), effective as of March 1, 2013, as amended (the “Agreement”) and now desire to further amend the Agreement in accordance with the terms and conditions set forth in this Amendment.  If the terms and conditions set forth in this Amendment shall be in conflict with the Agreement, the terms and conditions of this Amendment shall control.  Any terms in initial capital letters or all capital letters used as a defined term but not defined in this Amendment shall have the meaning set forth in the Agreement.  Upon execution of this Amendment by the Parties, any subsequent reference to the Agreement between the Parties shall mean the Agreement as amended by this Amendment.  Except as amended by this Amendment, the terms and conditions set forth in the Agreement shall continue in full force and effect according to their terms.  This Amendment shall be effective as of the date last signed below (the “Effective Date”).  

 

 

WHEREAS, pursuant to the Agreement, CSG provides **** ************** ********, including **** ********, to Customer; and

 

WHEREAS, **** ******** have been implemented as an upgrade to Customer's current **** ************** ********; and

 

WHEREAS, **** ******** have been installed and replace Customer's previously existing **** ********.

 

 

NOW, THEREFORE, CSG and Customer agree as follows:

 

1.    Schedule F.1, of the Agreement, “LISTING OF PRODUCTS AND SERVICES INCLUDED IN THE BSC,” (i) Subsection X, “**** ************** ********,” and (ii) Subsection XI, “******* ******** - *********,” shall be amended such that references therein to “****” shall be deleted and replaced as “****.”

 

 

IN WITNESS WHEREOF, CSG and Customer cause this Amendment to be duly executed below.

 

		
	
COMCAST CABLE COMMUNICATIONS MANAGEMENT, LLC (“CUSTOMER”)

 
	
CSG SYSTEMS, INC. (“CSG”)

	
 

By: /s/ Jeur Abeln
	
 

By:  /s/ Gregory L. Cannon

	
 

Name: Jeur Abeln
	
 

Name:  Gregory L. Cannon

	
 

Title:  Senior Vice President Procurement
	
 

Title:  SVP, Secretary & General Counsel

	
 

Date:  7-11-2018
	
 

Date:  May 4, 2018

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}]]